Core Viewpoint - The approval of the sodium bicarbonate injection by the National Medical Products Administration is expected to enhance market expansion and sales for the company, although it will not have a significant impact on current performance [1]. Company Summary - The full subsidiary of China National Pharmaceutical Group, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd., received the approval notice for the supplementary application of sodium bicarbonate injection [1]. - The sodium bicarbonate injection is classified as an antacid and is indicated for the treatment of metabolic acidosis and the prevention of uric acid kidney stones [1]. - The company has invested approximately 2.7442 million in research and development for this product [1]. Industry Summary - The estimated sales for public medical institutions nationwide in 2024 for sodium bicarbonate injection are approximately 580 million [1]. - Other companies that have passed the consistency evaluation include Hefei Yuanfengshun Pharmaceutical Technology Co., Ltd. [1].

Core Viewpoint - The company, China National Pharmaceutical Group Modern (国药现代), announced that its wholly-owned subsidiary, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd. (国药容生), received approval from the National Medical Products Administration for a supplemental application regarding sodium bicarbonate injection, allowing for an increase in specifications and passing the consistency evaluation of generic drug quality and efficacy [1]. Group 1 - The sodium bicarbonate injection is classified as an antacid and is indicated for the treatment of metabolic acidosis [1]. - It is also used for the prevention of uric acid kidney stones, reducing the nephrotoxicity of sulfonamide drugs, and preventing hemoglobin deposition in renal tubules during acute hemolysis [1]. - Additionally, intravenous administration of this injection has non-specific therapeutic effects for certain drug poisonings, such as barbiturates, salicylates, and methanol [1].

Core Viewpoint - The announcement indicates that the wholly-owned subsidiary of China National Pharmaceutical Group, Weichida Pharmaceutical Co., Ltd., has successfully passed the GMP compliance inspection for its production lines, which is a significant milestone for the company as it prepares for the market launch of its product, Acarbose [1] Group 1 - Weichida Pharmaceutical received a GMP compliance inspection notice for its production lines in workshop 108 and the comprehensive raw material drug workshop [1] - The inspection covered the raw material drug Acarbose, marking the first GMP compliance check prior to the product's market launch [1] - The production lines in question are renovated old factory workshops, with a total construction investment of approximately 22.76 million yuan [1] Group 2 - The current production capacity for Acarbose is designed at 12 tons per year [1]

规格：10ml:0.84g 注册分类：化学药品 证券代码：600420 证券简称：国药现代 公告编号：2025-070 上海现代制药股份有限公司 关于全资子公司获得药品补充申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，上海现代制药股份有限公司（以下简称公司）全资子公司国药集团容 生制药有限公司（以下简称国药容生）收到国家药品监督管理局核准签发的《药 品补充申请批准通知书》，批准碳酸氢钠注射液增加规格并通过仿制药质量和疗 效一致性评价（以下简称一致性评价），核发药品批准文号。现将相关情况公告 如下： 一、药品基本信息 药品名称：碳酸氢钠注射液 通知书编号：2025B04233 剂型：注射剂 证券代码：600420 证券简称：国药现代 公告编号：2025-070 用于尿酸性肾结石的预防，减少磺胺类药物的肾毒性，及急性溶血防止血红蛋白 沉积在肾小管；（3）静脉滴注对某些药物中毒有非特异性的治疗作用，如巴比 妥类、水杨酸类药物及甲醇等中毒。 药品批准文号：国药准字 H20258193 上市许可持有人：国药 ...

上海现代制药股份有限公司 关于全资子公司通过药品GMP符合性检查的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600420 证券简称：国药现代 公告编号：2025-071 | 生产线名称 | 目前主要生产产品及设计产能 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 车间、综合原料药车间 | 线 | 阿卡波糖，设计产能 | 吨/年 | 108 | III | 12 | 近日，上海现代制药股份有限公司（以下简称公司）全资子公司国药集团威 奇达药业有限公司（以下简称国药威奇达）收到药品 GMP 符合性检查告知书， 国药威奇达的 108 车间、综合原料药车间相关生产线通过 GMP 符合性检查。现 将相关情况公告如下： 一、基本信息 企业名称：国药集团威奇达药业有限公司 生产地址：山西省大同市经济技术开发区医药工业园区 检查范围：原料药（阿卡波糖）（108车间、综合原料药车间III线） 告知书编号：SX2025029 检查时间：2025年05月08 ...

证券代码：600420 证券简称：国药现代 公告编号：2025-069 上海现代制药股份有限公司 关于参加 2025 年上海辖区上市公司集体接待日 暨中报业绩说明会活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 9 月 19 日（周五）14:00 前访问 http://ir.p5w.net/zj/ 或扫描问题征集专题页面二维码进入问题征集专题页面进行会前提问。公司将在 说明会上对投资者普遍关注的问题进行回答。 上海现代制药股份有限公司（以下简称公司）已于 2025 年 8 月 30 日披露了 《2025 年半年度报告》。为进一步加强与投资者的互动交流，便于广大投资者 更全面深入地了解公司经营成果、财务状况，公司计划于 2025 年 9 月 19 日参加 2025 年上海辖区上市公司集体接待日暨中报业绩说明会，就投资者关心的问题 进行交流。 3、召开方式：本次活动将采用网络文字互动的方式举行 三、公司参会人员 董事、总裁：刘勇 会议召开时间：2025 年 9 月 19 日（星 ...

Group 1 - The core point of the article is that Guoyao Modern announced a cash dividend distribution plan for the first half of 2025, with a cash dividend of 0.10 yuan per share (tax included) [1] - The record date for the dividend is set for September 15, 2025, while the ex-dividend date and the date of cash dividend distribution are both scheduled for September 16, 2025 [1] - The total cash dividend to be distributed amounts to 134,117,269.20 yuan, based on the company's total share capital of 1,341,172,692 shares prior to the implementation of the plan [1]

证券代码：600420 证券简称：国药现代 公告编号：2025-068 上海现代制药股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.10元（含税） 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | 股 A | 2025/9/15 | － | 2025/9/16 | 2025/9/16 | 差异化分红送转： 否 一、通过分配方案的股东会届次和日期 2025 年 6 月 26 日，上海现代制药股份有限公司（以下简称公司）召开 2024 年年度股东大会，审议通过了《关于 2025 年中期分红安排的议案》，授权董事会 决定 2025 年半年度利润分配有关事宜。 2025 年 8 月 28 日，公司召开第八届董事会第二十三次会议，审议通过了《2025 年中期利润分配方案》。 二、分配方案 1. 发放年度：2025年半年度 三 ...

Core Points - The Shanghai Modern Pharmaceutical Co., Ltd. is holding its second extraordinary general meeting of shareholders in 2025 to ensure the orderly conduct of the meeting and protect shareholders' rights [1][2] - The meeting will include the election of a new board member and the revision of the "Management Measures for the Use of Raised Funds" [3][4] Meeting Details - The meeting is scheduled for September 15, 2025, at 14:30, located at the company's office in Shanghai [2] - Attendees will include registered shareholders, company directors, senior management, and legal representatives [2] Agenda Items - **Election of Directors**: The board has nominated Mr. Cai Maisong as a candidate for the board of directors, pending shareholder approval [3][4] - **Revision of Fund Management Guidelines**: The company proposes to amend its "Management Measures for the Use of Raised Funds" to enhance operational standards and compliance with regulatory requirements [4][14] Key Revisions in Fund Management - The revised guidelines specify that raised funds must be used exclusively for disclosed investment projects and cannot be used for supplementing working capital or repaying bank loans [4][11] - The management of raised funds must adhere to principles of safety, efficiency, and transparency [14][15] - The company must establish a dedicated account for raised funds, ensuring that these funds are not mixed with other financial resources [15][16] Compliance and Reporting - The company is required to provide detailed reports on the use of raised funds, including any changes in project timelines or funding allocations [19][30] - Independent auditors will review the management and usage of raised funds annually, ensuring compliance with the revised guidelines [30][32]

上海现代制药股份有限公司 2025 年第二次临时股东会 会议资料 2025 年 09 月 | | | 上海现代制药股份有限公司 2025 年第二次临时股东会会议资料 上海现代制药股份有限公司 2025 年第二次临时股东会会议须知 为维护全体股东的合法权益，确保上海现代制药股份有限公司（简称公司或 国药现代）股东会的正常秩序和议事效率，根据中国证券监督管理委员会《上市 公司股东会规则》及《公司章程》等的有关规定，特制定股东会须知，望出席股 东会的全体人员遵照执行： 1、公司根据《公司法》《证券法》《上市公司股东会规则》及《公司章程》 等有关规定，认真做好召开股东会的各项工作。 2、出席会议的股东依法享有发言权、咨询权、表决权等各项权利，但需由 公司统一安排发言和解答。 3、股东会采取现场投票与网络投票相结合的方式进行。 现场会议股东以其所持有的有表决权的股份数额行使表决权，每一股份享有 一票表决权。股东在投票表决时，应当在表决票中每项议案下设的"同意"、"反 对"、"弃权"三项中任选一项，并以打"√"表示。未填、错填、涂改、字迹无 法辨认的表决票视为无效。 网络投票方式详见公司发布的《关于召开 2025 年第二 ...